名家匯(300506.SZ):擬收購大話神遊20%股權
格隆匯5月27日丨名家匯(300506.SZ)公佈,公司於2020年5月27日召開的第三屆董事會第二十六次會議審議通過了《關於收購控股子公司少數股東股權的議案》,同意公司收購陳崢、彭德成、張金玉持有的北京大話神遊光影科技發展有限公司(“大話神遊”、“標的公司”)20%股權,交易對價為0元人民幣。
此次交易完成後,大話神遊將成為公司全資子公司,此次交易不構成關聯交易。
收購完成後,大話神遊將成為公司全資子公司,有利於進一步加強公司的管控力度,提高決策效率。此次收購符合公司的整體發展戰略,不會對公司財務狀況及未來發展等造成重大不利影響,不存在損害公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.